Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088965 | 0.90 | CYP1A2 (0.62) | CYP1A2CYP3A4POLBRAB9AKMT2A | |
| SCHEMBL3980301 | 0.83 | CYP1A2 (0.54) | CYP1A2CYP3A4POLBRAB9AKMT2A | |
| SCHEMBL3978108 | 0.83 | CYP1A2 (0.77) | SLC1A3SLC1A2SLC1A1CYP1A2CYP3A4 | |
| SCHEMBL3984275 | 0.83 | CYP1A2 (0.54) | CYP1A2CYP3A4POLBRAB9AKMT2A | |
| SCHEMBL3984222 | 0.82 | CYP1A2 (0.57) | SLC1A3SLC1A2SLC1A1CYP1A2CYP3A4 | |
| SCHEMBL13612898 | 0.81 | CYP1A2 (0.54) | CYP1A2CYP3A4POLBRAB9AKMT2A | |
| SCHEMBL3978079 | 0.81 | CYP3A4 (0.68) | SLC1A3SLC1A2SLC1A1CYP1A2CYP3A4 | |
| SCHEMBL3973701 | 0.79 | RAB9A (0.54) | SLC1A3SLC1A2SLC1A1CYP1A2CYP3A4 | |
| SCHEMBL3977078 | 0.79 | CYP1A2 (0.54) | SLC1A3SLC1A2SLC1A1CYP1A2CYP3A4 | |
| SCHEMBL4253135 | 0.78 | MAPT (0.59) | CYP1A2CYP3A4POLBRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101522184-A | Thiourea compounds | NAT HEALTH RESEARCH INSTITUTES (CN) | 2009-09-02 | — | — | CN | disclosed |
| EP-2056810-A2 | THIOUREA COMPOUNDS | National Health Research Institutes (TW) | 2009-05-13 | — | — | EP | disclosed |
| US-20080113975-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-05-15 | — | — | US | disclosed |
| US-20080113975-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-05-15 | — | — | US | disclosed |
| US-20080113975-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-05-15 | — | — | US | disclosed |
| US-20080096875-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-04-24 | — | — | US | disclosed |
| US-20080096875-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-04-24 | — | — | US | disclosed |
| US-20080096875-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-04-24 | — | — | US | disclosed |
| WO-2008022204-A2 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-02-21 | — | — | WO | disclosed |
| US-6562840-B1 | Non-peptidic inhibitors of proteolytic enzymes such as urokinase | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-6403633-B2 | USEFUL ANTIANGIOGENIC, ANTIARTHRITIC, ANTIINFLAMMATORY, ANTIRESTENOTIC, ANTIINVASIVE, ANTIMETASTIC, ANTIOSTEOPOROTIC, ANTIRETINOPATHIC, CONTRACEPTIVE AND TUMORISTATIC TREATMENT AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1152759-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | disclosed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| EP-1054886-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000047194-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096875-A1 | THIOUREA COMPOUNDS | TPMT, HAVCR2, ETV6 | SLC1A3 1879/4885SLC1A2 2277/4885SLC1A1 1953/4885 |
| US-20080113975-A1 | THIOUREA COMPOUNDS | TPMT, HAVCR2, EIF2AK2 | SLC1A3 1757/4885SLC1A2 2330/4885SLC1A1 1729/4885 |
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | C1S, C1R, C9 | SLC1A3 3104/4885SLC1A2 3966/4885SLC1A1 3545/4885 |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | SLC1A3 4300/4885SLC1A2 4009/4885SLC1A1 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.